Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250562 · ClinicalTrials.gov registry record · Phase 3
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,171
- Enrollment target
NCT00250562: Completed Phase 3 study, sponsored by Novartis.
NCT00250562 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,171 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00250562, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,171 participants
- Enrollment target
Study Summary
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected patients6. This fixed combination is registered in most countries worldwide. The potential benefits of these combinations should be evaluated in patients not adequately controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and tolerability of adding HCTZ 12.5 mg to valsartan 80 mg in those hypertensive patients. This study is not recruiting in the US.
Interventions
- DRUG valsartan plus hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,171 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00250562 record still lists
NCT00250562 is an interventional study that assigns participants to a tested intervention. Its 1,171 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% higher).
The record links to 0 conditions, and to 1 intervention - of which valsartan plus hydrochlorothiazide is the first listed.
NCT00250562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00250562 about?
NCT00250562 is a clinical study titled "A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.". Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been shown to have additive ef...
What is the current status of trial NCT00250562?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,171 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00250562?
The interventions under investigation include: valsartan plus hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00250562?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00250562's enrollment target sits among peer trials
1,171 236th of 2000 higher than 1,765 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06469788 · 1,170 participants · NA
Testimonials and Navigation in Rheumatology
- NCT04275557 · 1,174 participants
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
- NCT06133322 · 1,176 participants · NA
Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia